Project Grant R01HL173322
Award Date
7/15/24
Completion Date
6/30/28
Dollars Obligated
$1.4M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $637,526 to Duke University to conduct research on the role of sickle red blood cells (RBCs) in activating neutrophils and promoting vaso-occlusion in sickle cell disease (SCD). The key objectives of the research are to: 1) delineate the characteristics of sickle RBCs that contribute to neutrophil activation, 2) examine the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $685,884 to the University of North Carolina at Chapel Hill to conduct research on the regulation of coagulation and thrombosis by C1 inhibitor. The research aims to elucidate the molecular mechanisms by which endogenous C1 inhibitor regulates coagulation and venous thrombosis, evaluate the impact of C1 inhibitor deficiency on coagulation...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $827,753.90 to support research on the role of thiol isomerases in promoting vaso-occlusive events in sickle cell disease. The research aims to mechanistically examine how these redox-sensitive enzymes catalyze cysteine electron transferring events that contribute to platelet and neutrophil activation, thrombosis, and...
This $299,790 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of novel allosteric modulators of the thrombin receptor, protease-activated receptor 1 (PAR1), called Parmodulins, for the treatment of sickle cell disease (SCD). The project aims to identify optimized Parmodulins with improved potency and oral activity, and confirm their efficacy in mouse models of SCD, including...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund research to investigate the role of heme-induced complement activation in sickle cell disease (SCD) pregnancy. The $202,366 award, spanning September 1, 2024 to August 31, 2025, will support a study using a mouse model of SCD to characterize the effects of SCD and heme-induced complement activation on pregnancy outcomes (Aim 1), and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is focused on characterizing the role of the alternative complement pathway in the pathogenesis of acute chest syndrome (ACS) in sickle cell disease (SCD). The key objectives are to: 1) define the mechanisms by which complement contributes to the development of ACS using novel preclinical models, microfluidics, and in vitro assays; 2) characterize...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $764,817 to the University of North Carolina at Chapel Hill to conduct research on the mechanisms of coagulopathy and bleeding in acute promyelocytic leukemia (APL). The study aims to determine the individual contributions of the podoplanin-CLEC-2 pathway, the S100/Annexin A2/tissue plasminogen activator and the urokinase-type plasminogen...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to evaluate methods for improving the homing and engraftment efficiency of CD34+ cells from sickle cell disease (SCD) patients. The $128,100 award to the New York Blood Center, Inc. will support research to determine if co-infusing the CD34+ cells with their flow-through accessory cells, normally discarded after CD34+ cell...
This Project Grant award, valued at $607,535, was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research to investigate the effects of the breakdown product hemin on the pulmonary endothelium and its contribution to the pulmonary complications of sickle cell disease, including acute chest syndrome and pulmonary hypertension. The research aims to evaluate the specific effects of...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) totaling $1,276,908 to Bloodworks, a nonprofit organization in Seattle, WA. The grant, titled "Molecular and Translational Studies in Hematologic Disorders," will fund research focused on understanding the mechanisms of disease in von Willebrand disease and sickle cell disease, both of which involve von Willebrand factor. The proposed studies will investigate...